体外研究 (In Vitro) |
LYRM03 (50-200 μM; 6-24 h) 孵育 6、12 或 24 小时后,对 NR8383 大鼠肺泡巨噬细胞的活力无影响。 LYRM03 (50-200 μM; 24 h) 可呈剂量依赖性降低 LPS 诱导的 NR8383 大鼠肺泡巨噬细胞培养上清中 TNF-α、IL-1β 和 IL-18 水平的升高 (孵育 24 小时后)。 LYRM03 (50-200 μM; 24 h) 呈剂量依赖性抑制脂多糖 (LPS) 诱导的 NR8383 大鼠肺泡巨噬细胞中 NF-κB/TLR4/MyD88 信号通路的激活。 LYRM03 (50-200 μM; 24 h) 呈剂量依赖性抑制脂多糖 (LPS) 诱导的 NR8383 大鼠肺泡巨噬细胞中 NLRP3 炎症小体的上调。 LYRM03 (50-500 µmol/L; 1 h pre-incubation + 2 h, 4 h, 16 h, 24 h LPS treatment) 可抑制脂多糖 (LPS) 诱导的小鼠肺泡巨噬细胞中炎症介质的表达及一氧化氮生成,在 50 至 500 µmol/L 的浓度范围内可呈剂量依赖性抑制 iNOS、COX-2 和 Myd88 的表达。 LYRM03 (100 µmol/L; 1 h pre-incubation + 5-60 min LPS stimulation) 可通过抑制 LPS 诱导的 IκB 降解和 p38 MAPK 磷酸化,在 100 µmol/L 浓度下抑制小鼠肺泡巨噬细胞中依赖 Myd88 的 TLR4 信号通路。 LYRM03 (10-100 μg/mL; 1 h) 在 50 μg/mL 和 100 μg/mL 浓度下可将乳腺癌 MDA-MB-231 细胞中的 APN 酶活性抑制 50% 以上,且不会改变 APN 蛋白表达。 LYRM03 (10-100 μg/mL; 6-48 h) 在浓度高达 100 μg/mL、孵育时间长达 48 h 的条件下,诱导乳腺癌 MDA-MB-231 细胞的死亡率低于 20%。 LYRM03 (10-100 μg/mL; 6-48 h) 在浓度高达 100 μg/mL、孵育时间长达 48 h 的条件下,不会诱导乳腺癌 MDA-MB-231 细胞发生显著凋亡。 LYRM03 (10-100 μg/mL; 6-24 h) 可在伤口愈合实验中剂量依赖性地抑制乳腺癌 MDA-MB-231 细胞的迁移,其中以 100 μg/mL 作用 24 h 的效果最强。 LYRM03 (50-100 μg/mL; 10 days) 可在 50 μg/mL 和 100 μg/mL 浓度下作用 10 天,减少乳腺癌 MDA-MB-231 细胞的集落形成。
Cell Viability Assay
| Cell Line: |
NR8383 rat alveolar macrophage cell line |
| Concentration: |
50 μM; 100 μM; 200 μM |
| Incubation Time: |
6 h; 12 h; 24 h |
| Result: |
Showed no significant alteration in cell viability in any group treated with LYRM03, with or without LPS stimulation, relative to the Sham group (p > 0.05). |
ELISA Assay
| Cell Line: |
NR8383 rat alveolar macrophage cell line |
| Concentration: |
50 μM; 100 μM; 200 μM |
| Incubation Time: |
24 h after LPS stimulation |
| Result: |
Reduced LPS-induced elevated levels of TNF-α, IL-1β, and IL-18 in cell supernatants relative to the LPS-only group (p < 0.05). Exhibited no effect on cytokine levels when used alone. |
Western Blot Analysis
| Cell Line: |
murine alveolar macrophages |
| Concentration: |
100 µmol/L (pre-incubation for 1 h, LPS stimulation for 5, 15, 30, 45, 60 min) |
| Incubation Time: |
1 h pre-incubation + 5, 15, 30, 45, 60 min LPS stimulation |
| Result: |
Significantly reduced LPS-induced IκB degradation at 15, 30, and 45 min post-LPS stimulation. Significantly inhibited LPS-induced p38 MAPK phosphorylation at 15, 30, 45, and 60 min post-LPS stimulation, while total p38 protein levels remained unchanged. |
Apoptosis Analysis
| Cell Line: |
MDA-MB-231 |
| Concentration: |
10 μg/mL; 50 μg/mL; 100 μg/mL |
| Incubation Time: |
6 h; 12 h; 24 h; 48 h |
| Result: |
Detected no significant cleaved PARP expression via western blot. Showed no significant increase in apoptotic cells in any treated group compared to untreated controls via flow cytometry. |
|
体内研究 (In Vivo) |
LYRM03 (腹腔注射;LPS 暴露后 1 h 和 12 h 给予;5-20 mg/kg) 可呈剂量依赖性地对大鼠 LPS 诱导的急性肺损伤发挥保护作用,其中 20 mg/kg 剂量对肺损伤评分、炎症标志物、氧化应激及 NF-κB/TLR4/NLRP3 通路激活的抑制作用最为显著。 LYRM03 (20 mg/kg;腹腔注射;单次) 对健康大鼠的肺损伤、氧化应激、炎症反应或 NF-κB/TLR4/NLRP3 通路活性均无显著影响。 LYRM03 (腹腔注射,10 mg/kg) 可有效缓解雄性 C57BL/6 小鼠中 LPS 诱导的急性肺损伤,通过抑制 Myd88 依赖的 TLR4 信号通路减少炎症细胞浸润、促炎细胞因子产生及肺组织损伤。 LYRM03 (腹腔注射;于 LPS 给予后 1 h 和 12 h 给予,剂量为 5-20 mg/kg) 可呈剂量依赖性地保护大鼠免受 LPS 诱导的急性肺损伤,其中 20 mg/kg 剂量的作用最强,可通过抑制 NF-κB/MyD88/TLR4 轴、减轻氧化应激、炎症反应及肺细胞凋亡发挥作用。 LYRM03 (100 mg/kg;腹腔注射;每周 3 次) 可在 MDA-MB-231 乳腺癌 SCID 小鼠模型中强效减少肺转移灶的形成。
| Animal Model: |
Sprague-Dawley rats (220-250 g; LPS-induced acute lung injury) |
| Dosage: |
5 mg/kg; 10 mg/kg; 20 mg/kg |
| Administration: |
i.p.; at 1 and 12 h after LPS exposure |
| Result: |
Reduced LPS-induced lung injury scores, lung wet/dry weight ratio, and protein content in BALF in a dose-dependent manner. Decreased LPS-induced increases in myeloperoxidase (MPO) activity in lung tissue, serum malondialdehyde (MDA) levels, and serum levels of TNF-α, IL-1β, and IL-18 in a dose-dependent manner. Increased serum superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) levels in a dose-dependent manner. Inhibited LPS-induced upregulation of TLR4, MyD88, p-IKKα, p-IKKβ, p-IκBα, p-NF-κB protein and mRNA levels, as well as NLRP3, ASC, and caspase-1 protein and mRNA levels in lung tissue in a dose-dependent manner. Increased lung injury scores when administered at 20 mg/kg alongside siRNA targeting NF-κB p65, TLR4, or NLRP3 compared to rats treated with 20 mg/kg LYRM03 plus LPS alone. |
| Animal Model: |
Sprague-Dawley rats (220-250 g; healthy) |
| Dosage: |
20 mg/kg |
| Administration: |
i.p.; single administration |
| Result: |
Did not alter lung injury scores, lung wet/dry weight ratio, BALF protein content, lung MPO activity, serum MDA, SOD, or GSH-Px levels, or serum TNF-α, IL-1β, or IL-18 levels compared to sham-treated rats. Did not affect TLR4, MyD88, NF-κB pathway components, or NLRP3 inflammasome protein and mRNA levels in lung tissue. |
| Animal Model: |
C57BL/6 (male, 6-12 weeks old, 22 g, Specific Pathogen-Free, intratracheal LPS-induced ALI) |
| Dosage: |
10 mg/kg |
| Administration: |
i.p.; single dose (4-h groups); two doses, at time of LPS challenge and 12 hours post-challenge (24-h groups) |
| Result: |
Reduced LPS-induced BALF total protein concentration by approximately 32.7% at 4 hours. Significantly reduced BALF total protein concentration at 24 hours. Significantly decreased LPS-induced myeloperoxidase (MPO) activity in lung tissue at both 4 and 24 hours. Attenuated LPS-induced inflammatory cell infiltration and inter-alveolar septal thickening in lung tissue at 4 and 24 hours. Reduced LPS-induced mRNA expression of TNF-α, IL-1β, IL-6, and MIP-2 in lung tissue to approximately 30% of LPS-only levels at 4 hours. Significantly decreased BALF concentrations of IL-6 and TNF-α at 4 hours. Significantly suppressed LPS-induced iNOS and COX-2 protein expression in lung tissue at 24 hours. |
| Animal Model: |
Sprague-Dawley (adult male, 250-300 g, LPS-induced acute lung injury) |
| Dosage: |
5 mg/kg; 10 mg/kg; 20 mg/kg |
| Administration: |
i.p.; administered at 1 and 12 h after LPS |
| Result: |
Reduced lung injury score to 11.50, lung wet-dry weight ratio to 6.311, BALF protein to 75.37 mg/mL at 5 mg/kg. Reduced lung injury score to 8.205, lung wet-dry weight ratio to 5.750, BALF protein to 61.81 mg/mL at 10 mg/kg. Reduced lung injury score to 6.700, lung wet-dry weight ratio to 5.580, BALF protein to 52.55 mg/mL at 20 mg/kg. Reduced BALF TNF-α to 222.6 pg/mL, IL-1β to 394.1 pg/mL, IL-6 to 403.4 pg/mL at 5 mg/kg. Reduced BALF TNF-α to 129.6 pg/mL, IL-1β to 375.2 pg/mL, IL-6 to 274.1 pg/mL at 10 mg/kg. Reduced BALF TNF-α to 93.84 pg/mL, IL-1β to 357.7 pg/mL, IL-6 to 271.5 pg/mL at 20 mg/kg. Reduced pulmonary MPO activity to 0.3043 U/g, serum MDA to 63.33 nmol/mL, and increased serum SOD to 13.16 U/mL, serum GSH-Px to 132.5 U/mL at 5 mg/kg. Reduced pulmonary MPO activity to 0.2749 U/g, serum MDA to 41.98 nmol/mL, and increased serum SOD to 15.46 U/mL, serum GSH-Px to 162.1 U/mL at 10 mg/kg. Reduced pulmonary MPO activity to 0.2039 U/g, serum MDA to 30.12 nmol/mL, and increased serum SOD to 19.54 U/mL, serum GSH-Px to 198.8 U/mL at 20 mg/kg. Reduced serum TNF-α to 90.79 pg/mL, IL-8 to 1125 pg/mL, IL-6 to 345.6 pg/mL at 5 mg/kg. Reduced serum TNF-α to 58.95 pg/mL, IL-8 to 1040 pg/mL, IL-6 to 283.2 pg/mL at 10 mg/kg. Reduced serum TNF-α to 53.43 pg/mL, IL-8 to 904.9 pg/mL, IL-6 to 161.5 pg/mL at 20 mg/kg. Reduced lung protein levels of TLR4 to 2.255, NF-kB to 2.228, and increased IkB-α to 0.5054 at 5 mg/kg. Reduced lung protein levels of TLR4 to 1.942, HMGB1 to 2.039, MyD88 to 1.775, NF-kB to 2.187, and increased IkB-α to 0.6831 at 10 mg/kg. Reduced lung protein levels of TLR4 to 1.702, HMGB1 to 1.674, MyD88 to 1.441, NF-kB to 1.852, and increased IkB-α to 0.6996 at 20 mg/kg; corresponding mRNA expression of TLR4, HMGB1, MyD88, and NF-kB was also significantly reduced, while IkB-α mRNA was increased across all doses. Reduced apoptotic index to 42.99%, Cleaved Caspase 3 protein to 5.544, BAX protein to 4.811, and increased Cleaved PARP protein to 0.5449, Bcl-2 protein to 0.6006 at 5 mg/kg. Reduced apoptotic index to 33.51%, Cleaved Caspase 3 protein to 3.625, BAX protein to 4.247, and increased Cleaved PARP protein to 0.6978, Bcl-2 protein to 0.7134 at 10 mg/kg. Reduced apoptotic index to 28.60%, Cleaved Caspase 3 protein to 2.496, BAX protein to 3.385, and increased Cleaved PARP protein to 0.8879, Bcl-2 protein to 0.7743 at 20 mg/kg. |
| Animal Model: |
SCID mice (female) |
| Dosage: |
100 mg/kg |
| Administration: |
i.p.; 3 times per week |
| Result: |
Showed significantly fewer metastatic foci compared to control mice. Demonstrated better inhibition of lung metastasis than bestatin. |
|